Cargando…

Biologic Therapy in Head and Neck Cancer: A Road with Hurdles

The epidermal growth factor receptor (EGFR) is overexpressed in the vast majority of cases of squamous cell carcinoma of the head and neck (SCCHN). A high EGFR expression is associated with an unfavorable prognosis. Cetuximab is a chimeric human/murine IgG1 antibody which binds with high affinity to...

Descripción completa

Detalles Bibliográficos
Autores principales: Specenier, Pol, Vermorken, Jan B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scholarly Research Network 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382358/
https://www.ncbi.nlm.nih.gov/pubmed/22745915
http://dx.doi.org/10.5402/2012/163752
_version_ 1782236487794819072
author Specenier, Pol
Vermorken, Jan B.
author_facet Specenier, Pol
Vermorken, Jan B.
author_sort Specenier, Pol
collection PubMed
description The epidermal growth factor receptor (EGFR) is overexpressed in the vast majority of cases of squamous cell carcinoma of the head and neck (SCCHN). A high EGFR expression is associated with an unfavorable prognosis. Cetuximab is a chimeric human/murine IgG1 antibody which binds with high affinity to the EGFR. It is the only targeted agent which got approval for the treatment of SCCHN from the regulatory agencies of Europe and the United States, both in locoregionally advanced disease, in association with radiation, and in recurrent/metastatic disease. The outcome of trials involving other EGFR-directed monoclonal antibodies, that is, zalutumumab and panitumumab, was consistent with the results with cetuximab. However these trials failed to meet their primary endpoint. The results with EGFR-directed tyrosine kinase inhibitors have been disappointing. Other potential targets for treatment in SCCHN include the entire ErbB family, the vascular endothelial growth factor (VEGF) and its receptor (VEGFR), the insulin-like growth factor 1 receptor (IGF-1R), the insulin receptor (IR), histone deacetylases (HDAC), the mammalian target of rapamycin (mTOR), the platelet-derived growth factor receptor (PDGFR), heat-shock protein 90 (HSP90), nuclear factor-kappa B (NF-κB), aurora A or B, and phosphatidylinositol 3-kinase (PIK3CA).
format Online
Article
Text
id pubmed-3382358
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher International Scholarly Research Network
record_format MEDLINE/PubMed
spelling pubmed-33823582012-06-28 Biologic Therapy in Head and Neck Cancer: A Road with Hurdles Specenier, Pol Vermorken, Jan B. ISRN Oncol Review Article The epidermal growth factor receptor (EGFR) is overexpressed in the vast majority of cases of squamous cell carcinoma of the head and neck (SCCHN). A high EGFR expression is associated with an unfavorable prognosis. Cetuximab is a chimeric human/murine IgG1 antibody which binds with high affinity to the EGFR. It is the only targeted agent which got approval for the treatment of SCCHN from the regulatory agencies of Europe and the United States, both in locoregionally advanced disease, in association with radiation, and in recurrent/metastatic disease. The outcome of trials involving other EGFR-directed monoclonal antibodies, that is, zalutumumab and panitumumab, was consistent with the results with cetuximab. However these trials failed to meet their primary endpoint. The results with EGFR-directed tyrosine kinase inhibitors have been disappointing. Other potential targets for treatment in SCCHN include the entire ErbB family, the vascular endothelial growth factor (VEGF) and its receptor (VEGFR), the insulin-like growth factor 1 receptor (IGF-1R), the insulin receptor (IR), histone deacetylases (HDAC), the mammalian target of rapamycin (mTOR), the platelet-derived growth factor receptor (PDGFR), heat-shock protein 90 (HSP90), nuclear factor-kappa B (NF-κB), aurora A or B, and phosphatidylinositol 3-kinase (PIK3CA). International Scholarly Research Network 2012-06-13 /pmc/articles/PMC3382358/ /pubmed/22745915 http://dx.doi.org/10.5402/2012/163752 Text en Copyright © 2012 P. Specenier and J. B. Vermorken. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Specenier, Pol
Vermorken, Jan B.
Biologic Therapy in Head and Neck Cancer: A Road with Hurdles
title Biologic Therapy in Head and Neck Cancer: A Road with Hurdles
title_full Biologic Therapy in Head and Neck Cancer: A Road with Hurdles
title_fullStr Biologic Therapy in Head and Neck Cancer: A Road with Hurdles
title_full_unstemmed Biologic Therapy in Head and Neck Cancer: A Road with Hurdles
title_short Biologic Therapy in Head and Neck Cancer: A Road with Hurdles
title_sort biologic therapy in head and neck cancer: a road with hurdles
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382358/
https://www.ncbi.nlm.nih.gov/pubmed/22745915
http://dx.doi.org/10.5402/2012/163752
work_keys_str_mv AT specenierpol biologictherapyinheadandneckcanceraroadwithhurdles
AT vermorkenjanb biologictherapyinheadandneckcanceraroadwithhurdles